HILS RSI Chart
Last 7 days
-4.8%
Last 30 days
-0.8%
Last 90 days
9.8%
Trailing 12 Months
465779.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 216.3K | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 152.6K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jul 14, 2022 | appajosyula sireesh | gifted | - | - | -75,757 | - |
Jul 14, 2022 | appajosyula sireesh | gifted | - | - | 7,576 | - |
Jun 17, 2022 | milby randy | bought | 389 | 0.7799 | 500 | chief executive officer |
Jun 06, 2022 | milby randy | bought | 688 | 0.688463 | 1,000 | chief executive officer |
Jun 01, 2022 | milby randy | bought | 0.94 | 0.94 | 1.00 | chief executive officer |
May 25, 2022 | milby randy | bought | 786 | 0.786 | 1,000 | chief executive officer |
May 20, 2022 | milby randy | bought | 918 | 0.91825 | 1,000 | chief executive officer |
May 19, 2022 | milby randy | bought | 907 | 0.90765 | 1,000 | chief executive officer |
Apr 18, 2022 | milby randy | acquired | 24,341 | 0.101203 | 240,526 | chief executive officer |
Jan 14, 2022 | milby randy | acquired | 884,125 | 3.2 | 276,289 | chief executive officer |
Which funds bought or sold HILS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -10,041 | - | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | new | - | 4,481 | 4,481 | -% |
May 15, 2024 | TWO SIGMA ADVISERS, LP | new | - | 5,464 | 5,464 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 11.25 | -42.00 | 646 | -% |
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | new | - | 6,000 | 6,000 | -% |
May 13, 2024 | XTX Topco Ltd | new | - | 7,361 | 7,361 | -% |
May 10, 2024 | JPMORGAN CHASE & CO | new | - | 1.00 | 1.00 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 325 | 4.00 | 7.00 | -% |
May 06, 2024 | Warberg Asset Management LLC | unchanged | - | -788 | 4,303 | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Unveiling Hillstream BioPharma, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Hillstream BioPharma, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.57 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Hillstream BioPharma, Inc. News
Income Statement (Quarterly) | ||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 |
Revenue | 66.1% | 96.00 | 58.00 | 28.00 | 34.00 | 32.00 |
Operating Expenses | -7.3% | 2,347 | 2,531 | 1,845 | 2,365 | 2,714 |
S&GA Expenses | -100.0% | - | 1,538 | 1,357 | 1,334 | 1,667 |
R&D Expenses | 3.3% | 1,025 | 993 | 488 | 1,031 | 1,048 |
Interest Expenses | 1227.7% | 5.00 | 354* | 3.00 | 7.00 | 6.00 |
Net Income | 8.8% | -2,256 | -2,473 | -1,820 | -2,336 | -2,688 |
Net Income Margin | 32.7% | -41.09* | -61.06* | - | - | - |
Free Cashflow | -100.0% | -2,800 | -1,400 | -900 | -1,500 | -3,500 |
Balance Sheet | ||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2020Q4 |
Assets | -18.8% | 8,887 | 10,946 | 3,167 | 4,599 | 4,722 | 6,689 | 8,018 | 10,248 | 12,091 | 622 | - |
Current Assets | -18.8% | 8,887 | 10,946 | 3,167 | 4,599 | 4,722 | 6,689 | 8,018 | 10,248 | 12,091 | 622 | 295 |
Cash Equivalents | -22.9% | 8,427 | 10,935 | 2,689 | 3,904 | 3,569 | 6,511 | 7,597 | 9,484 | 11,122 | 4.00 | 192 |
Liabilities | 1.3% | 1,838 | 1,815 | 1,410 | 1,530 | 1,521 | 1,145 | 902 | 1,208 | 1,752 | 5,307 | 4,012 |
Current Liabilities | 1.3% | 1,838 | 1,815 | 1,410 | 1,530 | 1,521 | 1,145 | 902 | 1,208 | 1,752 | 4,534 | 2,725 |
Shareholder's Equity | -22.8% | 7,049 | 9,131 | 1,757 | 3,069 | 3,201 | 5,544 | 7,116 | 9,040 | 10,339 | - | - |
Retained Earnings | -9.3% | -27,000 | -24,703 | -22,229 | -20,409 | -18,072 | -15,384 | -13,617 | -11,490 | -9,853 | -6,911 | -4,704 |
Additional Paid-In Capital | 0.5% | 34,078 | 33,904 | 24,055 | 23,547 | 21,342 | 20,998 | 20,795 | 20,554 | 20,191 | 2,226 | 986 |
Shares Outstanding | 0.4% | 11,790 | 11,740 | 17,512 | 16,814 | 11,514 | - | 11,532 | 11,104 | 11,364 | 6,357 | 6,357 |
Float | - | - | - | - | 3,900 | - | - | - | 5,600 | - | - | - |
Cashflow (Quarterly) | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Cashflow From Operations | -100.0% | -2,800 | -1,400 | -900 | -1,500 | -3,500 | -892 | -1,548 | -1,373 | -2,742 | -7.67 | -316 | -269 | -492 | - |
Share Based Compensation | -9.9% | 154 | 170 | 158 | 158 | 345 | 202 | 241 | 339 | 19.00 | 7.00 | 4.00 | 554 | 674 | - |
Cashflow From Financing | -96.7% | 317 | 9,662 | -306 | 1,846 | 523 | -193 | -338 | -249 | 13,846 | -33.06 | 333 | 276 | 323 | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses | ||
Research and development | $ 1,025,258 | $ 1,047,677 |
General and administrative | 1,322,045 | 1,666,721 |
Total operating expenses | 2,347,303 | 2,714,398 |
Loss from operations | (2,347,303) | (2,714,398) |
Other income (expense) | ||
Interest expense | (4,700) | (6,138) |
Interest income | 95,894 | 32,248 |
Total other income (expense), net | 91,194 | 26,110 |
Net loss | $ (2,256,109) | $ (2,688,288) |
Net loss per share: | ||
Basic | $ (0.19) | $ (5.84) |
Diluted | $ (0.19) | $ (5.84) |
Weighted average number of common shares outstanding: | ||
Basic | 11,757,808 | 460,580 |
Diluted | 11,757,808 | 460,580 |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash | $ 8,427,290 | $ 10,935,352 |
Prepaid expenses and other current assets | 460,007 | 11,041 |
Total current assets | 8,887,297 | 10,946,393 |
Total assets | 8,887,297 | 10,946,393 |
Current liabilities | ||
Accounts payable | 993,244 | 908,577 |
Accrued expenses | 527,527 | 906,469 |
Insurance premium financing liability | 317,119 | |
Total current liabilities | 1,837,890 | 1,815,046 |
Total liabilities | 1,837,890 | 1,815,046 |
Commitments and contingencies (see Note 5) | ||
Stockholders’ equity | ||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||
Common stock, $0.0001 par value, 250,000,000 shares authorized, 11,793,309 shares and 11,743,309 shares issued and 11,789,676 shares and 11,739,676 shares outstanding as of March 31, 2024 and December 31, 2023, respectively | 1,180 | 1,175 |
Additional paid-in capital | 34,077,827 | 33,903,663 |
Accumulated deficit | (26,959,635) | (24,703,526) |
Treasury stock, at cost, 3,633 shares held in treasury as of March 31, 2024 and December 31, 2023 | (69,965) | (69,965) |
Total stockholders’ equity | 7,049,407 | 9,131,347 |
Total liabilities and stockholders’ equity | $ 8,887,297 | $ 10,946,393 |